Huntingdon Life Sciences
Professional services
UnclaimedA former international contract research organization specializing in preclinical and non-clinical safety studies.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Huntingdon Life Sciences was an international contract research organization (CRO) that conducted preclinical and non-clinical research for pharmaceutical, chemical, food, agricultural and other industrial customers. The company originated in Cambridgeshire, England, in 1951 as Nutrition Research Co. Ltd., a commercial research business focused initially on nutrition, veterinary science and biochemistry. Over time, its work expanded into pharmaceuticals, food additives, industrial chemicals, crop-protection products and broader toxicology and biological-safety testing. The business benefited from the growth of regulatory testing requirements in the 1960s, particularly in pharmaceuticals. Becton Dickinson acquired the company in 1964 and later reorganized it as Huntingdon Research Centre PLC. During the 1980s and early 1990s, Huntingdon expanded through public-market financing and acquisitions in the United Kingdom and United States. It bought or established businesses involved in analytical testing, toxicology, engineering, environmental services and related laboratory work. This diversification made the wider group substantially broader than a conventional life-sciences CRO, although the life-sciences division ultimately remained its most strategically important activity. Huntingdon strengthened its core research operations in 1995 by acquiring the toxicology business of Applied Biosciences International, together with the Leicester Clinical Research Centre and facilities in Britain and the United States. In 1997, the group adopted the Huntingdon Life Sciences name, with the British subsidiary operating as Huntingdon Life Sciences and the United States operation as Huntingdon Life Sciences Inc. Its principal laboratories were located in Huntingdon, Cambridgeshire; Eye, Suffolk; and East Millstone, New Jersey, with an office in Tokyo. Public figures available from 2008 indicated a workforce of more than 1,600 employees, making it one of Europe's largest non-clinical CROs and one of the largest globally. The company's customers were principally pharmaceutical companies, but more than one-third of its business reportedly came from non-pharmaceutical sectors. Crop protection was a major component of that non-pharmaceutical work. Its services included toxicology, laboratory safety assessment, biological research and testing of pharmaceuticals, agricultural chemicals, industrial substances and consumer-related products. Animal research, including work involving non-human primates and beagles, was central to the company's operating model and became the defining source of public controversy around the brand. Huntingdon was subjected to sustained criticism from animal-rights and animal-welfare organizations. Undercover investigations in the United Kingdom in 1997 and the United States in 1998 generated allegations of mistreatment and inadequate laboratory practices. The British investigation led to criminal convictions of two laboratory technicians after television footage showed abusive treatment of dogs. The company dismissed the employees involved and introduced new management and training practices. The American investigation by a PETA operative produced further allegations concerning the treatment of laboratory animals; company executives disputed aspects of the interpretation of the footage. Beginning in 1999, the Stop Huntingdon Animal Cruelty (SHAC) campaign attempted to close the company by targeting Huntingdon, its customers, suppliers, financial institutions and business associates. The campaign contributed to severe commercial and reputational pressure, including the loss of a New York Stock Exchange listing after the company's market capitalization fell below exchange requirements and the closure of its bank account by the Royal Bank of Scotland. British authorities later supported the company with banking arrangements through the Bank of England. SHAC-related convictions followed in the United Kingdom, including convictions for conspiracy to blackmail and prison sentences for threatening Huntingdon personnel. In 2002, Huntingdon moved its financial center to the United States and was incorporated in Maryland under the name Life Sciences Research. The company was acquired in 2009. In September 2015, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates were combined to form Envigo, ending Huntingdon Life Sciences as a distinct operating brand. Envigo was subsequently acquired by Inotiv in 2021, but that later corporate development does not make Huntingdon Life Sciences an active standalone brand.
History
Huntingdon Life Sciences began in 1951 in Cambridgeshire as Nutrition Research Co. Ltd., a commercial laboratory devoted to nutrition, veterinary and biochemical research. Its original operations were divided between offices in Huntingdon and laboratories at the Hartford Field Station. The company later adopted the name Nutritional Research Unit Ltd. and broadened its research into pharmaceuticals, food additives, industrial chemicals and consumer substances. The expansion of government testing requirements during the 1960s created favorable conditions for the business, especially in pharmaceutical safety research. Becton Dickinson acquired the company in 1964. In 1983 it established Huntingdon Research Centre PLC and offered American depositary receipts representing the business. The group changed its name to Huntingdon International Holdings plc in 1985 and created Huntingdon Analytical Services in the United States. During the second half of the 1980s and early 1990s, Huntingdon pursued an acquisition-led growth strategy. It purchased testing and laboratory businesses including Twin City Testing Laboratory, Nebraska Testing Corporation, Travis Laboratories, Kansas City Test Laboratory and Southwestern Laboratories. It also entered engineering and environmental consulting through acquisitions such as Northern Engineering and Testing, Empire Soils Investigations, Chen Associates, Asteco, Austin Research Engineers and other businesses. By the early 1990s the group had three principal divisions: life sciences, engineering and environmental services, and the Travers Morgan engineering group. The engineering and environmental interests were later sold, while Travers Morgan ultimately failed, leaving life sciences as the group's central long-term business. In 1995, Huntingdon acquired the toxicology operations of Applied Biosciences International for $32.5 million in cash, together with the Leicester Clinical Research Centre. The transaction added a United States laboratory near Princeton, New Jersey, and two British facilities. In 1997, Huntingdon International Holdings became Huntingdon Life Sciences Group, while Huntingdon Research Centre adopted the Huntingdon Life Sciences name and the American business operated as Huntingdon Life Sciences Inc. The group was listed in London and had also obtained a New York Stock Exchange listing during its earlier expansion. Animal testing became the company's most prominent public issue. In 1997, footage recorded covertly at a British facility showed technicians abusing dogs. The employees were suspended and dismissed, and two were convicted under the Protection of Animals Act 1911. The incident led to a management change and new training and openness measures. A second undercover investigation in 1998 at the New Jersey operation generated further allegations from PETA. HLS president Alan Staple said that a monkey shown during a dissection was sedated, disputing the suggestion that it was conscious. These episodes helped trigger a prolonged campaign by animal-rights activists. Stop Huntingdon Animal Cruelty began operating in 1999 in the United Kingdom and United States. It sought to close HLS by demonstrating outside the company's sites and applying pressure to customers, suppliers, banks, contractors and other associated organizations. The campaign was accompanied by intimidation and criminal acts attributed to some activists, including threats and an assault on managing director Brian Cass. The campaign contributed to severe financial and banking difficulties. In 2000, HLS lost its New York Stock Exchange listing after its market value fell below exchange rules. The Royal Bank of Scotland closed its account, after which the British government arranged access to a Bank of England account. Police and prosecutors later responded to the campaign through arrests and prosecutions. Operation Achilles in 2007 involved hundreds of officers and raids in several countries. Seven senior SHAC figures were convicted of conspiracy to blackmail in 2008, and five activists received prison sentences in 2010 for threatening HLS staff. These actions reduced the intensity of attacks, although the campaign and broader debate over animal research continued. In 2002, the company moved its financial center to the United States and incorporated in Maryland as Life Sciences Research. It continued to provide non-clinical research and safety-testing services from facilities in Huntingdon, Eye and East Millstone, with an office in Tokyo. Publicly available figures from 2008 described a workforce of more than 1,600 people. In 2009, HLS was acquired, although the supplied reference material does not identify the acquirer. In September 2015, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates merged into Envigo. The merger ended Huntingdon Life Sciences as a separate operating brand.
- 2015
Merged into Envigo
[1]HLS was combined with Harlan Laboratories, GFA, NDA Analytics and LSR associates to form Envigo.
- 2009
Acquired
[1]Huntingdon Life Sciences was acquired; the supplied reference does not identify the acquirer.
- 2002
Financial center moved to the United States
[1]The company incorporated in Maryland as Life Sciences Research.
- 2000
Lost New York Stock Exchange listing
[1]The listing ended after the company's market capitalization fell below exchange requirements.
- 1997
Adopted the Huntingdon Life Sciences name
[1]Huntingdon International Holdings became Huntingdon Life Sciences Group, while its British and American operating businesses adopted related HLS names.
- 1995
Acquired Applied Biosciences toxicology operations
[1]The acquisition added toxicology capabilities, a New Jersey laboratory and British research facilities.
- 1989
New York Stock Exchange listing
[1]The company obtained a New York Stock Exchange listing.
- 1988
London flotation
[1]Huntingdon was floated on the London Stock Exchange during its acquisition and international expansion phase.
- 1985
Expanded into the United States
[1]The group changed its name to Huntingdon International Holdings and established Huntingdon Analytical Services in the United States.
- 1983
Huntingdon Research Centre PLC created
[1]Becton Dickinson reorganized the business and offered American depositary receipts representing its interest.
Products and positioning
A large, internationally operating CRO positioned around outsourced preclinical, toxicology and regulatory safety research for pharmaceutical and chemical-industry clients.
Contract research services
Preclinical pharmaceutical research
HLS performed outsourced non-clinical research for pharmaceutical customers before products entered or progressed through human clinical development. Its work supported biological characterization, safety assessment and regulatory submissions rather than the sale of medicines under an HLS consumer brand.
Laboratory testing services
Toxicology and biological safety assessment
Toxicology was a core capability of the company, covering the assessment of potential harms from pharmaceutical, chemical and other substances. The service portfolio formed part of HLS's broader non-clinical biological-safety offering and was supported by laboratories in Britain and the United States.
Regulatory testing services
Crop-protection and agricultural-chemical testing
HLS tested crop-protection products and related agricultural chemicals for commercial and regulatory purposes. Crop protection was reported to represent a substantial share of the company's non-pharmaceutical business, alongside work for pharmaceutical clients and other industries.
Chemical safety services
Industrial and consumer-chemical testing
The company conducted research and safety evaluations involving industrial chemicals, food additives and consumer-related substances. These services extended the business beyond pharmaceutical research and made HLS a contractor for multiple regulated industries.
Controversies
1999
Animal-rights intimidation campaign
Some activists associated with the anti-HLS campaign were accused or convicted of threats, assaults, blackmail, hoax threats and other intimidation. The incidents included an attack on managing director Brian Cass and threats against HLS personnel and business associates.
1998
United States undercover investigation
A PETA investigator recorded material inside the New Jersey laboratories and alleged serious mistreatment of research animals. HLS president Alan Staple disputed the interpretation of footage involving a monkey, stating that the animal was sedated.
1997
British undercover investigation into laboratory-dog treatment
Secretly recorded footage broadcast on television showed technicians abusing beagles and other alleged breaches of animal-protection requirements. The employees were dismissed, two were convicted of cruelty, and HLS introduced management and training changes.
Marketing campaigns
- 2007Operation Achilles
United Kingdom · Netherlands · Belgium
Police conducted coordinated raids and arrests against people connected with SHAC in response to alleged intimidation, threats and blackmail directed at HLS and its associates.
Outcome. Seven leading SHAC figures were later convicted of conspiracy to blackmail, and police said the operation substantially reduced violent activism connected with the campaign.
- 1999Stop Huntingdon Animal Cruelty
United Kingdom · United States
SHAC sought to shut down HLS because of its use of animals in biomedical and chemical research. It combined demonstrations, lobbying and direct action with pressure on the company's customers, suppliers, banks, contractors and other commercial partners.
Outcome. The campaign caused substantial reputational, banking and market pressure, including HLS's loss of its New York Stock Exchange listing. Criminal prosecutions of senior activists and a major police operation reduced the intensity of attacks, but did not end the broader dispute over animal experimentation.
Brand decisions
2015
Merge HLS into EnvigoM&ABackground
HLS and several related laboratory and analytics businesses were consolidated into a larger contract-research platform.
Action taken
Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates merged to form Envigo.
Aftermath
Huntingdon Life Sciences ceased to operate as a distinct standalone brand.
2002
Move financial center to the United StatesStrategyBackground
The group was increasingly international and had significant United States operations.
Action taken
HLS moved its financial center to the United States and incorporated in Maryland as Life Sciences Research.
Aftermath
The corporate structure reflected the company's American operating and financial presence while its principal research facilities remained in both the United Kingdom and United States.
1995
Acquire Applied Biosciences International toxicology operationsM&ABackground
HLS wanted to enlarge its CRO business and strengthen its presence in the United States.
Action taken
It acquired the toxicology business, the Leicester Clinical Research Centre and associated United States and British facilities for $32.5 million in cash plus the clinical research center.
Aftermath
The transaction expanded HLS's toxicology capacity and geographic reach.
Cash consideration. $32.5 million plus the Leicester Clinical Research Centre (1995 transaction)
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/huntingdon-life-sciences · Editorial policy · How profiles are compiled